Block & Leviton Probes Stryker Securities Fraud
Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 14, 2026
The probe adds legal and reputational risk to Stryker after an 8 percent share drop tied to the unresolved manufacturing issue, pressuring the stock and raising the possibility of securities litigation costs. Broader medical device and healthcare investors may reassess disclosure and supply-chain risk, though the direct market impact remains largely company-specific.
Block & Leviton LLP announced it is investigating Stryker Corporation (NYSE: SYK) and certain of its executives for potential violations of federal securities laws. According to the firm, on July 30, 2026, Stryker's CEO told investors that the company had addressed a manufacturing problem affecting inventory supply in its peripheral vascular business, an issue management said it expected to resolve during the third quarter. On September 8, 2026, however, Stryker's CFO disclosed at the Wells Fargo Healthcare Conference that the manufacturing problem remained unresolved and was now expected to persist into the fourth quarter. Stryker shares fell roughly 8 percent on the news. The investigation concerns whether Stryker misrepresented the status of the manufacturing problem and the health of its business to investors. Block & Leviton states it may file an action to attempt to recover losses on behalf of investors who lost money, and it encourages whistleblowers with non-public information to assist its investigation or file a report with the United States — United States Securities and Exchange Commission under its whistleblower program, which may pay rewards of up to 30 percent of any successful recovery. The notices are attorney advertising and no lawsuit has been confirmed as filed.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard